R&D

Dear Research Advocate: Yesterday, along with 85 partner organizations (more than ever before!), we celebrated Public Health Thank You Day . Hundreds of people took to social media with the hashtag #PHTYD to celebrate and thank the public health heroes who work 24/7 to maximize community health and safety. Overall, PHTYD garnered 10.1 million impressions on Twitter. Leaders in the field, including CDC Director Brenda Fitzgerald, NIH Director Francis Collins, Surgeon General Jerome Adams, APHA Executive Director Georges Benjamin, and World Bank President Jim Kim added their voices to the overwhelming chorus of appreciation. Late last week, news broke of promising discussions in both...
Dear Research Advocate: Yesterday, a high energy discussion on Advocating for Basic Science in a Disease-Focused World at the Society for Neuroscience conference once again revealed the strong appetite for advocacy among scientists, and young scientists in particular. The audience resonated with my point that “you can’t outsource advocacy,” and many were inspired to tweet on the spot. In case you doubt the impact of scientists engaging in advocacy, consider this: Research!America’s Board Chair, former Congressman (R-DE) and Governor Mike Castle, was recently interviewed by the Society for Neuroscience: “Scientists deepened my understanding of the promise of embryonic stem cell research...
U.S. investments in medical and health research and development (R&D) grew by 13.3% over a three year period (2013 – 2015), according to Research!America’s new investment report . However, medical and health R&D represents a small fraction of total spending on health. Currently, the U.S. spends less than 5 cents of every health dollar on R&D to prevent, treat, and cure disease. More than half of Americans (56%) say that is not enough, a recent public opinion survey shows. Industry, including pharmaceutical, medical technolo­gy, biotechnology and health IT companies, invests more in R&D than other sectors. In 2015, industry invested 64.7% of total spending, followed by the...
Dear Research Advocate: While Senate leadership had originally planned to pass a continuing resolution (CR) this week and leave town, negotiations are ongoing. Odds still are that a short-term CR providing $1.1 billion in emergency Zika funding will be signed into law before the 9/30/16 deadline. We’ll keep you posted. The 21st Century Cures Initiative (Cures) is on hold once again. Earlier today, House Energy and Commerce Committee Chairman Fred Upton’s (R-MI-06) staff reported progress on a compromise bill crafted to pass both houses of Congress this year, but said it will not be considered until after the elections. Cures advocacy may have a “rock of Sisyphus” feel to it, but there’s...
For athletes and spectators who are attending the Olympic Games this month, the threat of deadly antibiotic resistant bacteria is all too real. Recently the “bad bug” carbapenemase-producing Klebsiella pneumonia (KPC) was discovered in the waters off several beaches of Rio, where rowing, canoeing and swimming events are scheduled to occur. KPC is one example of antibiotic resistant bacteria, which already sicken at least two million Americans every year. If people visiting Rio for the Olympics become infected with KPC, they may bring it back home, quickly spreading this dangerous bacterium around the world. Without support for new antibiotic R&D, such as the 21 st Century Cures Act,...
More than 1.6 million people developed cancer in the U.S. in 2015, and 1 in 2 men and 1 in 3 women will be diagnosed with cancer over the course of their lives. Cancer also has a major fiscal impact: the economic burden totaled $263.8 billion in 2013, translating to nearly $900 per American. On March 10, 2016, Research!America, in partnership with AcademyHealth, American Cancer Society, and Celgene Corporation convened a panel of cancer experts to discuss how research is working to stop cancer. Dr. Lisa Simpson, president and CEO of AcademyHealth, started the conversation by outlining cancer innovation as a continuum. Basic research provides answers on how living organisms work and what...
Dear Research Advocate, This holiday season, Congress has delivered a most welcome package with plenty of trimmings for patients and all of us who care about the future of health. The bipartisan deal-making is complete. A final short-term spending measure, expiring Tuesday, December 22, allows the House and Senate time to review and pass a spending bill and tax package before adjourning for the year. These two major pieces of legislation represent a real win for research; the jumpstart we need to restore the NIH budget to robust annual growth and fuel a new era of medical innovation and global leadership in both public and private sectors. As federal policymakers consider how to vote on...
Strange bedfellows? Not when it comes to research advocacy. On Monday, former House Speaker Newt Gingrich joined Senator Elizabeth Warren (D-MA) and Representative Elijah Cummings (D-MD-07) to press for more R&D in the bioscience arena. Not every topic is one on which Senator Warren and Speaker Gingrich agree , but they found common ground in the benefits that could come from another NIH doubling. The drumbeat for medical research continues apace. The Bipartisan Policy Center (BPC) released what is sure to be an influential report this week, Advancing Medical Innovation for a Healthier America . Focused on the development phase of the discovery, development, delivery continuum, the...
A global solution and removing barriers to antibiotic development are necessary to combat antimicrobial resistance (AMR). Representatives from various research and health sectors discussed strategies for fighting superbugs at a BIO International Convention super session today. The panel agreed there must be a greater focus on streamlining clinical trials and harmonizing the global regulatory process to support the development of new antibiotics. Jim O'Neill, chairman, Review on Antimicrobial Resistance, recommended the establishment of a global $2 billion AMR Innovation Fund over five years funded by industry to help jump start product development. Venture capitalist risk could stimulate...
Technology transfer, or the practice of transferring scientific findings from one organization, most notably universities, to another for further development, plays a pivotal role in the R&D ecosystem. It is the bridge that ensures knowledge cultivated through academic research reaches patients and other beneficiaries, and it is a critically important means of financing further science and technology at academic institutions in the U.S. and around the world. The Association of University Technology Managers (AUTM), a nonprofit organization with an international membership of more than 3,000 technology managers and business executives, has developed a project that not only highlights the...

Sidebar Quote

Luck shouldn't play a role in why I'm alive.
Laurie MacCaskill, a seven-year pancreatic cancer survivor